Table 3 Demographic and clinical characteristics of TTM cohort using CPC score
From: Circular RNAs to predict clinical outcome after cardiac arrest
Characteristics | Neurological outcome | p-value | |
|---|---|---|---|
CPC1-2 | CPC3-5 | ||
n = 286 | n = 256 | ||
Age, years | 60 (20–90) | 68 (35–94) | < 0.001 |
Sex | |||
 Male | 238 (83.2%) | 205 (80.1%) | 0.405 |
 Female | 48 (16.8%) | 51 (19.9%) | |
Co-morbidities | |||
 Hypertension | 101 (35.3%) | 124 (48.4%) | 0.003 |
 Diabetes mellitus | 31 (10.8%) | 44 (17.2%) | 0.044 |
 Heart failure | 7 (2.4%) | 20 (7.8%) | 0.008 |
 COPD | 18 (6.3%) | 31 (12.1%) | 0.027 |
First monitored rhythm | |||
 VF or non-perfusing VT | 260 (90.9%) | 170 (66.4%) | < 0.001 |
 Asystole or PEA | 17 (5.9%) | 77 (30.1%) | |
 ROSC after bystander defibrillation | 7 (2.4%) | 1 (0.4%) | |
 Unknown | 2 (0.7%) | 8 (3.1%) | |
Witnessed arrest | 262 (91.6%) | 223 (87.1%) | 0.118 |
Bystander CPR | 229 (80.1%) | 168 (65.6%) | < 0.001 |
Time from CA to ROSC, min | 20 (0–160) | 30 (0–170) | < 0.001 |
Initial serum lactate (mmol/l) | 4.4 (0–20) | 6.5 (0–21.3) | < 0.001 |
NSE 48 h after ROSC (ng/ml) | 15 (2.5–119.1) | 63.3 (3.1–782) | < 0.001 |
Shock on admission | 23 (8%) | 38 (14.8%) | 0.01 |